Newly created Algerian Agence Nationale des Products Pharmaceutiques leads drug registration and approval of pharmaceuticals, issues visas to import pharmaceutical products and medical devices for use in human medicine  

ELMWOOD PARK, N.J. – The Regulatory Harmonization Institute, Inc. (RHI), an international, not-for-profit association dedicated to global harmonization of drug and medical device regulatory requirements, has been selected to present a series of educational workshops in Algiers, Algeria designed for government regulatory officials, pharmaceutical manufacturers, laboratory and health professionals, and other stakeholders in regulatory approval processes. An initial two-day program conducted in April 2013 identified topics for in-depth discussions and presentations during a week-long series of forums in June 2013. Dean Erhardt, president of RHI and principal at D2 Pharma Consulting, says, “Activities in Algeria further extend the RHI mission: to enable more efficient delivery of high quality, safe and efficacious therapies to all patient populations by advancing global harmonization of regulatory requirements for medical products and devices intended for human use. We have also provided a positioning document for the government of Turkey, and anticipate that other emerging nations will request this level of support.” Joseph Carabello, RHI founder and president of CPR Strategic Marketing Communications, explains, “Our goal is to advance international cooperation between and among regulatory authorities and their constituent stakeholders, improving patient access to important medical products and mitigating unnecessary delays or product approvals across multiple countries. RHI is the only organization whose mission is solely focused on matters related to regulatory harmonization.” RHI is supported by members that include government agencies, public and private companies, patient advocacy groups, not-for-profit organizations, academic professionals and other industry groups.  In addition to its educational programs, RHI also generates government and private sector support for information exchange, product development, and investment. RHI activities focus upon:

1. Reducing the overall cost to bring products to market, assisting in maintaining viable manufacturer margins which can be invested in ongoing research for innovative drug therapies.
2. Reducing the drug lags from country to country, enabling unique innovator products to access new markets quicker and resulting in more innovative therapies being available to more patients.
3. Creating a reduced timeline to get less expensive products — generics and biosimilars — to new markets, assisting financially strapped governments in keeping down the cost of therapies.

About Regulatory Harmonization Institute: Regulatory Harmonization Institute, Inc. (RHI) is a non-profit association dedicated to global harmonization of regulatory requirements with a mission to influence the development and introduction of meaningful therapies to patients across the globe. RHI will advance global harmonization of regulatory requirements for medicines and devices intended for human use, enabling greater delivery of meaningful new therapies to all patient populations. Visit https://www.regharmonization.com.